Pros and cons of AI in digital patient recruitment: The future of clinical drug trials
If you’re ready to leverage emerging technology like AI into your patient recruitment and enrollment processes we’ve got some pros and cons that you can start considering today.
7 useful questions to ask before hiring a patient recruitment company
Asking about expertise, experience, and engagement methods can help you learn quickly whether a company is the right patient recruitment partner. Here are 7 questions to help you make the right decision.
6 digital metrics to track the effectiveness of your online clinical enrollment
It’s critical that clinical researchers and patient recruitment providers are on the same page. Keep track of these baseline digital metrics to learn about potential challenges before they impact your study.
Understanding patient motivation: Why do people enroll in clinical trials?
Patient motivation is driven by many different factors. But no matter the reason, understanding patient motivation gives us insights into who are more likely to enroll and improves our recruitment in the future.
Pre-screening vs. screening: Understanding the differences in patient recruitment
Comprehensive pre-screening is often overlooked in favor of keeping participant pools as large as possible for longer periods of time. Here’s why that’s very often a mistake and how it impacts your bottom line.
Decentralized Clinical Trials: Why pharma companies are going digital
What are some common challenges the healthcare industry is up against as a whole? And how exactly does decentralization improve patient retention and reduce trial costs?
Why customized patient outreach leads to accelerated enrollment
By understanding your target audience, you can create a more meaningful and engaging experience that drives recruitment and fills your clinical trial faster than you thought possible.
Back to basics: Everything you need to know about patient recruitment for clinical trials
Only 1 in 10 drug development projects make it all the way from Phase I to approval. Why is that number so low, and are there any patient enrollment solutions for the pharmaceutical industry as a whole?